Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of balinatunfib (SAR441566) in moderate to severe Crohn's disease
NL-OMON58821Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of balinatunfib in Crohn's disease (3 arms), sponsored by Sanofi. Primary endpoint: Proportion of participants achieving endoscopic response. Started Jun 2025; status: completed.
02
Drugs
balinatunfib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON58821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58821.